27 AprFull year 2022 results
Posted at 07:00hin Board, Novacyt Group, Uncategorizedby mandy_novacyt

Full year revenue and EBITDA in line with guidance

Accelerating product development post-COVID-19 to become a leading global clinical diagnostic company in infectious diseases

Paris, France and Eastleigh, UK 27 April 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its audited results for the year ended 31 December 2022.

Full year 2022 results

Attachments

Disclaimer

Novacyt SA published this content on 27 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2023 06:17:07 UTC.